The global Covid-19 outbreak has shaken up a lot of things, but Roche (OTCQX:RHHBY)
continues on with a steady growth trajectory. While there have been
some disruptions to a few drug franchises, and there could be more of an
impact in the second quarter, the outbreak has also been a time for
Roche’s large diagnostics business to shine. All told, Roche continues
to show its stripes as a consistent quality growth name in the
pharmaceutical space.
My bullish thesis for Roche
now leans more toward that stability and quality angle rather than pure
undervaluation. I believe the shares are priced for a high single-digit
total return, which isn’t exemplary, but isn’t bad either on a relative
basis.
Click here to continue:
Roche Looks Undervalued Given The Stability Of The Business
No comments:
Post a Comment